RU2012134351A - Способы лечения дисфункции мейбомиевых желез - Google Patents

Способы лечения дисфункции мейбомиевых желез Download PDF

Info

Publication number
RU2012134351A
RU2012134351A RU2012134351/15A RU2012134351A RU2012134351A RU 2012134351 A RU2012134351 A RU 2012134351A RU 2012134351/15 A RU2012134351/15 A RU 2012134351/15A RU 2012134351 A RU2012134351 A RU 2012134351A RU 2012134351 A RU2012134351 A RU 2012134351A
Authority
RU
Russia
Prior art keywords
meibomian glands
halogen atom
secretion
reduced
nhcor
Prior art date
Application number
RU2012134351/15A
Other languages
English (en)
Russian (ru)
Inventor
Джеймс Т. Далтон
Джитендра ЭСВАРАКА
Original Assignee
ДЖиТиЭкс, ИНК.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by ДЖиТиЭкс, ИНК. filed Critical ДЖиТиЭкс, ИНК.
Publication of RU2012134351A publication Critical patent/RU2012134351A/ru

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/16—Amides, e.g. hydroxamic acids
    • A61K31/165—Amides, e.g. hydroxamic acids having aromatic rings, e.g. colchicine, atenolol, progabide
    • A61K31/167—Amides, e.g. hydroxamic acids having aromatic rings, e.g. colchicine, atenolol, progabide having the nitrogen of a carboxamide group directly attached to the aromatic ring, e.g. lidocaine, paracetamol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/275—Nitriles; Isonitriles
    • A61K31/277—Nitriles; Isonitriles having a ring, e.g. verapamil
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/16—Amides, e.g. hydroxamic acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents

Landscapes

  • Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • General Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Public Health (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Ophthalmology & Optometry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pain & Pain Management (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicinal Preparation (AREA)
RU2012134351/15A 2010-01-11 2011-01-11 Способы лечения дисфункции мейбомиевых желез RU2012134351A (ru)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US29396610P 2010-01-11 2010-01-11
US61/293,966 2010-01-11
PCT/US2011/020871 WO2011085385A1 (en) 2010-01-11 2011-01-11 Methods of treating meibomian gland dysfunction

Publications (1)

Publication Number Publication Date
RU2012134351A true RU2012134351A (ru) 2014-02-20

Family

ID=44259000

Family Applications (1)

Application Number Title Priority Date Filing Date
RU2012134351/15A RU2012134351A (ru) 2010-01-11 2011-01-11 Способы лечения дисфункции мейбомиевых желез

Country Status (10)

Country Link
US (1) US8791158B2 (enExample)
EP (1) EP2523556A4 (enExample)
JP (1) JP2013516501A (enExample)
KR (1) KR20120115380A (enExample)
CN (1) CN103002737A (enExample)
AU (1) AU2011203832A1 (enExample)
CA (1) CA2787114A1 (enExample)
MX (1) MX2012008110A (enExample)
RU (1) RU2012134351A (enExample)
WO (1) WO2011085385A1 (enExample)

Families Citing this family (32)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US8915253B2 (en) 2005-07-18 2014-12-23 Tearscience, Inc. Method and apparatus for treating gland dysfunction employing heated medium
US7981095B2 (en) 2005-07-18 2011-07-19 Tearscience, Inc. Methods for treating meibomian gland dysfunction employing fluid jet
US8950405B2 (en) 2006-05-15 2015-02-10 Tearscience, Inc. Treatment of obstructive disorders of the eye or eyelid
US20070060988A1 (en) * 2005-07-18 2007-03-15 Grenon Stephen M Melting meibomian gland obstructions
US20090043365A1 (en) 2005-07-18 2009-02-12 Kolis Scientific, Inc. Methods, apparatuses, and systems for reducing intraocular pressure as a means of preventing or treating open-angle glaucoma
US20080114423A1 (en) 2006-05-15 2008-05-15 Grenon Stephen M Apparatus for inner eyelid treatment of meibomian gland dysfunction
WO2013003594A2 (en) 2011-06-28 2013-01-03 Tearscience, Inc. Methods and systems for treating meibomian gland dysfunction using radio-frequency energy
US7981145B2 (en) 2005-07-18 2011-07-19 Tearscience Inc. Treatment of meibomian glands
US8128674B2 (en) 2006-05-15 2012-03-06 Tearscience, Inc. System for outer eyelid heat and pressure treatment for treating meibomian gland dysfunction
US8137390B2 (en) 2006-05-15 2012-03-20 Tearscience, Inc. System for providing heat treatment and heat loss reduction for treating meibomian gland dysfunction
US9314369B2 (en) 2006-05-15 2016-04-19 Tearscience, Inc. System for inner eyelid treatment of meibomian gland dysfunction
US8128673B2 (en) 2006-05-15 2012-03-06 Tearscience, Inc. System for inner eyelid heat and pressure treatment for treating meibomian gland dysfunction
CN101528214B (zh) * 2006-08-24 2013-06-05 田纳西大学研究基金会 取代的n-酰基苯胺及其使用方法
US9381183B2 (en) * 2012-07-18 2016-07-05 Physicians Recommended Nutriceuticals, Llc Methods for improving the quality of the meibum composition of meibomian glands
US10314807B2 (en) 2012-07-13 2019-06-11 Gtx, Inc. Method of treating HER2-positive breast cancers with selective androgen receptor modulators (SARMS)
US9622992B2 (en) 2012-07-13 2017-04-18 Gtx, Inc. Method of treating androgen receptor (AR)-positive breast cancers with selective androgen receptor modulator (SARMs)
US10258596B2 (en) 2012-07-13 2019-04-16 Gtx, Inc. Method of treating HER2-positive breast cancers with selective androgen receptor modulators (SARMS)
PL2872482T3 (pl) 2012-07-13 2021-03-08 Oncternal Therapeutics, Inc. Sposób leczenia raków sutka z użyciem selektywnego modulatora receptora androgenowego (sarm)
US10987334B2 (en) 2012-07-13 2021-04-27 University Of Tennessee Research Foundation Method of treating ER mutant expressing breast cancers with selective androgen receptor modulators (SARMs)
US9744149B2 (en) 2012-07-13 2017-08-29 Gtx, Inc. Method of treating androgen receptor (AR)-positive breast cancers with selective androgen receptor modulator (SARMs)
US9969683B2 (en) 2012-07-13 2018-05-15 Gtx, Inc. Method of treating estrogen receptor (ER)-positive breast cancers with selective androgen receptor modulator (SARMS)
US10842670B2 (en) 2012-08-22 2020-11-24 Johnson & Johnson Vision Care, Inc. Apparatuses and methods for diagnosing and/or treating lipid transport deficiency in ocular tear films, and related components and devices
US10064818B2 (en) * 2013-08-28 2018-09-04 Presbyopia Therapies, LLC Compositions and methods for the treatment of presbyopia
US9463201B2 (en) 2014-10-19 2016-10-11 M.G. Therapeutics Ltd Compositions and methods for the treatment of meibomian gland dysfunction
RU2567829C1 (ru) * 2014-10-22 2015-11-10 Елизавета Геннадьевна Полунина Способ оценки морфофункционального состояния мейбомиевых желез - биометрия мейбомиевых желез
KR101714710B1 (ko) 2015-09-17 2017-03-10 고려대학교 산학협력단 마이봄샘 압출기
BR112018070852B1 (pt) * 2016-04-14 2024-01-16 Azura Ophthalmics Ltd Composições de dissulfeto de selênio
US20210251970A1 (en) 2018-10-10 2021-08-19 Presbyopia Therapies Inc Compositions and methods for storage stable ophthalmic drugs
EP4433053A4 (en) 2021-11-17 2025-09-17 Lenz Therapeutics Operations Inc ACECLIDINE DERIVATIVES, THEIR COMPOSITIONS AND METHODS OF USE
US20230168157A1 (en) * 2021-11-29 2023-06-01 Petróleo Brasileiro S.A. - Petrobras System and method for evaluation of the deposition in tubes of the furnaces of a delayed coking unit
US11648247B1 (en) 2021-12-16 2023-05-16 Lenz Therapeutics, Inc. Compositions and methods for the treatment of presbyopia
US12414942B1 (en) 2024-03-15 2025-09-16 Lenz Therapeutics Operations, Inc. Compositions, methods, and systems for treating presbyopia

Family Cites Families (48)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4407791A (en) * 1981-09-28 1983-10-04 Alcon Laboratories, Inc. Ophthalmic solutions
LU88769I2 (fr) * 1982-07-23 1996-11-05 Zeneca Ltd Bicalutamide et ses sels et esters pharmaceutiquement acceptables (Casodex (R))
US20050038110A1 (en) * 2000-08-24 2005-02-17 Steiner Mitchell S. Selective androgen receptor modulators and methods of use thereof
US6492554B2 (en) * 2000-08-24 2002-12-10 The University Of Tennessee Research Corporation Selective androgen receptor modulators and methods of use thereof
US6838484B2 (en) * 2000-08-24 2005-01-04 University Of Tennessee Research Foundation Formulations comprising selective androgen receptor modulators
US7645898B2 (en) * 2000-08-24 2010-01-12 University Of Tennessee Research Foundation Selective androgen receptor modulators and method of use thereof
US7026500B2 (en) * 2000-08-24 2006-04-11 University Of Tennessee Research Foundation Halogenated selective androgen receptor modulators and methods of use thereof
US7855229B2 (en) * 2000-08-24 2010-12-21 University Of Tennessee Research Foundation Treating wasting disorders with selective androgen receptor modulators
US7622503B2 (en) * 2000-08-24 2009-11-24 University Of Tennessee Research Foundation Selective androgen receptor modulators and methods of use thereof
US8445534B2 (en) * 2000-08-24 2013-05-21 University Of Tennessee Research Foundation Treating androgen decline in aging male (ADAM)-associated conditions with SARMs
US20070173546A1 (en) * 2000-08-24 2007-07-26 Dalton James T Selective androgen receptor modulators and method of use thereof
US6998500B2 (en) * 2000-08-24 2006-02-14 University Of Tennessee Research Foundation Selective androgen receptor modulators and methods of use thereof
US20040260108A1 (en) * 2001-06-25 2004-12-23 Dalton James T. Metabolites of selective androgen receptor modulators and methods of use thereof
US7919647B2 (en) * 2000-08-24 2011-04-05 University Of Tennessee Research Foundation Selective androgen receptor modulators and methods of use thereof
EP1325914A4 (en) * 2000-09-14 2004-11-17 Kaken Pharma Co Ltd TETRAHYDROQUINOLINE COMPOUNDS
US8853266B2 (en) * 2001-12-06 2014-10-07 University Of Tennessee Research Foundation Selective androgen receptor modulators for treating diabetes
US20070161608A1 (en) * 2001-12-06 2007-07-12 Dalton James T Selective androgen receptor modulators for treating muscle wasting
WO2003074449A2 (en) 2002-02-28 2003-09-12 University Of Tennessee Research Foundation Multi-substitued selective androgen receptor modulators and methods of use thereof
AU2003217303A1 (en) 2002-02-28 2003-09-16 University Of Tennessee Research Foundation Haloacetamide and azide substituted compounds and methods of use thereof
US7772433B2 (en) * 2002-02-28 2010-08-10 University Of Tennessee Research Foundation SARMS and method of use thereof
KR20040101251A (ko) * 2002-02-28 2004-12-02 유니버시티 오브 테네시 리서치 파운데이션 다치환된 선택적 안드로겐 수용체 모듈레이터 및 이를사용하는 방법
US7803970B2 (en) * 2002-02-28 2010-09-28 University Of Tennessee Research Foundation Multi-substitued selective androgen receptor modulators and methods of use thereof
HRP20050038A2 (en) 2002-06-17 2005-08-31 University Of Tennessee Research Foundation N-bridged selective androgen receptor modulators and methods of use thereof
EP1562906A4 (en) * 2002-10-15 2009-12-02 Univ Tennessee Res Foundation HETEROCYCLIC SELECTIVE ANDROGEN RECEPTOR MODULATORS AND METHOD FOR THEIR USE
US20040197928A1 (en) * 2002-10-15 2004-10-07 Dalton James T. Method for detecting selective androgen receptor modulators
US20040265916A1 (en) * 2002-10-15 2004-12-30 Dalton James T. Method for detecting selective androgen receptor modulators
EP1558232A4 (en) 2002-10-15 2008-07-02 Gtx Inc TREATMENT OF FAT SUPPORT WITH SELECTIVE ANDROGEN RECEPTOR MODULATORS
JP2006506369A (ja) 2002-10-15 2006-02-23 ユニバーシティ・オブ・テネシー・リサーチ・ファウンデーション メチレン架橋選択的アンドロゲン受容体調節剤及びその使用方法
US20060276539A1 (en) * 2002-10-16 2006-12-07 Dalton James T Treating Androgen Decline in Aging Male (ADAM)- associated conditions with SARMS
CA2501874A1 (en) 2002-10-16 2004-04-29 Gtx, Inc. Treating androgen decline in aging male (adam)-associated conditions with sarms
US20040087810A1 (en) * 2002-10-23 2004-05-06 Dalton James T. Irreversible selective androgen receptor modulators and methods of use thereof
US8309603B2 (en) * 2004-06-07 2012-11-13 University Of Tennessee Research Foundation SARMs and method of use thereof
AU2004204800B8 (en) * 2003-01-13 2011-05-26 University Of Tennessee Research Foundation Large-scale synthesis of selective androgen receptor modulators
JP2006516286A (ja) 2003-01-22 2006-06-29 ジーティーエックス・インコーポレイテッド Ｓａｒｍによる女性のアンドロゲン減少に関連する病気の治療
EA200501761A1 (ru) * 2003-12-16 2006-04-28 Джи Ти Икс, ИНК. Пролекарственные формы селективных модуляторов андрогеновых рецепторов и способы их применения
CA2552524A1 (en) * 2004-01-10 2005-07-28 Biolipid, Inc. Lipid compositions and methods of use
US20110237664A1 (en) 2004-06-07 2011-09-29 Dalton James T Selective androgen receptor modulators for treating diabetes
US20130034562A1 (en) * 2004-06-07 2013-02-07 Dalton James T Selective androgen receptor modulators for treating diabetes
MXPA06013958A (es) 2004-06-07 2007-03-15 Univ Tennessee Res Foundation Moduladores del receptor de androgenos selectivo metodos para utilizar los mismos.
EP2425715B1 (en) * 2005-08-31 2014-03-05 University of Tennessee Research Foundation Treating symptoms of renal disease with selective androgen receptor modulators (SARM)
JP4899625B2 (ja) * 2006-05-12 2012-03-21 スズキ株式会社 鞍乗型不整地走行車両
WO2008008433A2 (en) * 2006-07-12 2008-01-17 University Of Tennessee Research Foundation Substituted acylanilides and methods of use thereof
WO2008011072A2 (en) * 2006-07-19 2008-01-24 Osurf (Ohio State University Research Foundation) Selective androgen receptor modulators, analogs and derivatives thereof and uses thereof
CN101528214B (zh) * 2006-08-24 2013-06-05 田纳西大学研究基金会 取代的n-酰基苯胺及其使用方法
CN101668511A (zh) * 2007-02-28 2010-03-10 阿西克斯医疗公司 正常化睑板腺分泌的方法和化合物
US7968603B2 (en) * 2007-09-11 2011-06-28 University Of Tennessee Research Foundation Solid forms of selective androgen receptor modulators
WO2009036206A1 (en) * 2007-09-11 2009-03-19 University Of Tennessee Research Foundation Solid forms of selective androgen receptor modulators
EP2915529B1 (en) 2008-05-07 2017-06-14 The Regents of The University of California Therapeutic replenishment and enrichment of ocular surface lubrication

Also Published As

Publication number Publication date
AU2011203832A1 (en) 2012-08-23
US8791158B2 (en) 2014-07-29
CN103002737A (zh) 2013-03-27
JP2013516501A (ja) 2013-05-13
US20110172302A1 (en) 2011-07-14
CA2787114A1 (en) 2011-07-14
KR20120115380A (ko) 2012-10-17
WO2011085385A1 (en) 2011-07-14
MX2012008110A (es) 2012-10-03
EP2523556A1 (en) 2012-11-21
EP2523556A4 (en) 2013-08-28

Similar Documents

Publication Publication Date Title
RU2012134351A (ru) Способы лечения дисфункции мейбомиевых желез
JP2013516501A5 (enExample)
AU712927B2 (en) Pharmaceutical preparations comprised of salts of hyaluronic acid with local anaesthetics
US12403114B2 (en) Cannabinoid acid ester compositions and uses thereof
HRP20230052T1 (hr) Spojevi derivata 1,3,4-oksadiazol sulfonamida kao inhibitori histonske deacetilaze 6, i farmaceutski pripravak koji ih sadrži
RU2017112308A (ru) Композиции и способы для лечения бессонницы
ITFI20100113A1 (it) Spray nasale liquido contenente naltrexone a bassi dosaggi.
RU2018101473A (ru) Депо-препарат, содержащий сложный эфир лимонной кислоты
EP2854779A1 (en) Biomarkers for determining effective response of treatments of hepatocellular carcinoma (hcc) patients
BR112015026332A2 (pt) composição farmacêutica oral para a prevenção ou para o tratamento da síndrome do olho seco compreendendo rebamipida ou um profármaco da mesma
RU2017115726A (ru) Ингибиторы лизин-специфичного гингипаина
EA201300314A8 (ru) Композиции и лекарственное средство для лечения глазных болезней, устройство, содержащее композиции и лекарственное средство
JP6749962B2 (ja) 網脈絡膜障害の抑制剤
ES2324130B1 (es) Uso de derivados de mononitrato de dianhidrohexita como agentes reductores de la hipertension ocular.
JPWO2018203424A1 (ja) 点眼剤
WO2006049250A1 (ja) 眼内移行性促進水性点眼剤
CN105596336B (zh) 化合物sr8278在制备治疗i型糖尿病角膜病变药物中的应用
JP2018510855A5 (enExample)
US3374144A (en) Ophthalmic composition
RU2013148799A (ru) Дигидропиридины (клевидипин) кратковременного действия для применения в восстановлении после инсульта
JP2018533631A (ja) 網膜疾患の治療のためのミラベグロン
JP2019070026A (ja) 外用剤
CN107106566A (zh) 晶状体硬化抑制剂
WO2014204357A3 (ru) Лекарственное средство для лечения кератоконуса
CN106974916A (zh) 奥贝胆酸和二甲双胍的复方组合物及其应用

Legal Events

Date Code Title Description
FA92 Acknowledgement of application withdrawn (lack of supplementary materials submitted)

Effective date: 20150803